Skip to main content
Addgene

pLenti-CD74-ROS1 nonmutant
(Plasmid #183813)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 183813 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLenti
  • Backbone size w/o insert (bp) 7877
  • Total vector size (bp) 9430
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert 1

  • Gene/Insert name
    ROS Proto-Oncogene 1, Receptor Tyrosine Kinase
  • Alt name
    ROS1
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1488
  • GenBank ID
    NP_002935
  • Entrez Gene
    ROS1 (a.k.a. MCF3, ROS, c-ros-1)
  • Promoter CMV
  • Tag / Fusion Protein
    • The fusion protein of CD74 exon 1-6 and ROS1 exon 34-43

Cloning Information for Gene/Insert 1

Gene/Insert 2

  • Gene/Insert name
    CD74 molecule
  • Alt name
    CD74
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    625
  • GenBank ID
    NM_001025159.3
  • Entrez Gene
    CD74 (a.k.a. CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33)
  • Promoter CMV
  • Tag / Fusion Protein
    • The fusion protein of CD74 exon 1-6 and ROS1 exon 34-43

Cloning Information for Gene/Insert 2

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLenti-CD74-ROS1 nonmutant was a gift from Aaron Hata (Addgene plasmid # 183813 ; http://n2t.net/addgene:183813 ; RRID:Addgene_183813)
  • For your References section:

    Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8. 10.1158/1078-0432.CCR-21-0032 PubMed 33685866